Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
“We are delighted to have the backing of these sophisticated investors as we strive to develop novel immunotherapies that can provide durable clinical benefit for broad populations of cancer patients,” said Kevin Pojasek, Ph.D., President & Chief Executive Officer of Enara Bio. “Earlier this year, our EDAPT platform received strong external validation when Boehringer Ingelheim decided to exercise its option to license multiple Dark Antigens to develop off-the-shelf immunotherapies for lung cancer. The fundraise we are announcing today, led by two new strategic investors, reflects the quality of our science and further underlines not only the groundbreaking potential of Dark Antigens, but also our internal pipeline of first-in-class immunotherapies.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data